SGLT-2抑制剂在2型糖尿病合并心力衰竭患者中的临床应用

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (617 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effect of sodium-dependent glucose transporter-2 (SGLT-2) inhibitor in the treatment of type 2 diabetes mellitus complicated with heart failure. Methods A total of 80 patients with type 2 diabetes complicated with heart failure admitted to Xinyu People′s Hospital from January 2020 to January 2021 were selected as the research objects, they were divided into control group (40 cases) and observation group (40 cases) according to random number table method. Both groups were treated with conventional anti-heart failure therapy, the control group treated with conventional hypoglycemic treatment, and the observation group treated with SGLT-2 inhibitor hypoglycemic treatment. The incidence of blood glucose, inflammatory factors, oxidative stress and adverse reactions were compared between the two groups. Results There were no significant differences in fasting blood glucose (FPG) and 2 h postprandial blood glucose (2 h PG) levels between two groups before treatment (P>0.05). After treatment, the levels of FPG and 2 h PG in the two groups were lower than before treatment, and the levels of FPG and 2 h PG in the observation group were higher than those in the control group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in left ventricular ejection fraction (LVEF), output per wave (SV) and mitral valve inflow ratio (E/A) between two groups (P>0.05). After treatment, LVEF, SV and E/A in the two groups were higher than those before treatment, and LVEF, SV and E/A in the observation group were higher than those in the control group, the differences were statistically significant (P<0.05). There were no significant differences in the levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA) and superoxide dismutase (SOD) between two groups before treatment (P>0.05). After treatment, the levels of CRP, TNF-α and MDA in the two groups were lower than those before treatment, while SOD was higher than that before treatment, with statistical significances (P<0.05). After treatment, the levels of CRP, TNF-α and MDA in the observation group were lower than those in the control group, while the level of SOD was higher than that in the control group, with statistical significances (P<0.05). There was no significant difference in 6 min walking distance before treatment between two groups (P>0.05). The 6 min walking distance of the two groups after treatment was longer than that before treatment, and the distance of the observation group was longer than that of the control group, the differences were statistically significant (P<0.05). The rehospitalization rate of heart failure in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05), while there was no significant difference in cardiovascular mortality between the two groups (P>0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion SGLT-2 inhibitor has significant efficacy in patients with type 2 diabetes mellitus complicated with heart failure, such as promoting the improvement of heart function and controlling blood glucose level.

Key words： Sodium-dependent glucose transporter protein-2 Type 2 diabetes mellitus Heart failure Heart function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Qinghong
	HU Xiaowu
	XIA Jinlan

Cite this article:

ZENG Qinghong,HU Xiaowu,XIA Jinlan. Clinical application of SGLT-2 inhibitor in type 2 diabetes mellitus with heart failure[J]. 中国当代医药, 2022, 29(21): 14-17转22.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I21/14

[1]	吕晨燕，姜得悦，高迎，等.服用达格列净的2型糖尿病合并慢性心力衰竭患者左心室舒张功能改变的观察[J].中国糖尿病杂志，2020，28（3）：190-192.
[2]	唐晓笛，樊瑛.钠-葡萄糖协同转运蛋白抑制剂对合并射血分数保留型心力衰竭的2型糖尿病患者的心血管保护作用研究[J].临床心血管病杂志，2021，37（1）：68-72.
[3]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[4]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[5]	刘前桂，李永杰，郑曦，等.6分钟步行试验在呼吸康复训练中的临床应用[J].临床肺科杂志，2010，15（1）：129-131.
[6]	张秋林.胰岛素泵强化降糖治疗对合并冠心病的2型糖尿病患者血糖波动及胰岛素抵抗指数的作用分析[J].健康之友，2020，6（5）：170-171.
[7]	庄世虹，成蓓，贾海波，等.达格列净联合沙库巴曲缬沙坦治疗慢性心力衰竭合并2型糖尿病的疗效和结局[J].微循环学杂志，2021，31（1）：42-47，62.
[8]	郑刚.钠葡萄糖共转运蛋白2抑制剂对心力衰竭患者一级和二级预防作用临床研究的最新进展[J].中华老年心脑血1管病杂志，2020，22（12）：1336-1338.
[9]	李晨曦，杨帆，孟然，等.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病心血管获益及安全性的系统综述和Meta分析[J].中华糖尿病杂志，2020，12（9）：756-760.
[10]	杨莉，张旭东，詹小青，等.糖-钠协同转运蛋白2抑制剂对心力衰竭合并糖尿病小鼠治疗效果及左心室重构影响的实验研究[J].现代生物医学进展，2021，21（16）：3032-3037.
[11]	梁国钦，彭俊，魏文琦，等.血清NT-proBNP，PT3X与急性心肌梗死合并糖尿病患者预后的相关性研究[J].中国医学创新，2020，17（14）：132-135.
[12]	覃保瑜，刘红.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病合并心力衰竭的影响[J].医学综述，2021，27（21）：4300-4304.
[13]	Vijay N，Liu X，Chambless LE，et al.Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide：A Biomarker Approach to Predict Heart Failure Risk—The Atherosclerosis Risk in Communities Study[J].Clin Chem，2020，5（12）：1802-1810.
[14]	朱大龙，起家军，苏青，等.中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识[J].中华糖尿病杂志，2020，5（1）：1-12.
[15]	赵喆，杨丹丹，詹晓蓉.SGLT2抑制剂联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的研究进展[J].临床与病理杂志，2019，39（6）：1337-1341.